Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by PeterMacd2on Jun 16, 2019 12:55pm
121 Views
Post# 29830256

RE:RE:RE:Thoughts on Rec. 2.0 Regulations and where we are at

RE:RE:RE:Thoughts on Rec. 2.0 Regulations and where we are atThis inhaling vs ingestion difference is a result of the way CBD & THC compounds are handled by our bodies. Hemp plants seem to have very complex biochemistries. What's fascinating to me is that molecular biologists now are getting into the act to change Cannabis sativa plants genetically to produce more water-soluble CBD - THC (better assimilated by our bodies), and to greatly increases yields of the plants. I really hope APH is paying attention to these developments.  Trait suggests we will eventually see 2 to 5 times greater CBD production per plant, and plants more suitable to greehouse conditions, than the natural hemp strains available today.  https://traitbio.com/stable-transformation-of-hemp-3/
The reason I believe this to be probably true is the Chief Science Officer of Trait is a former senior researcher at Los Alamos Nat Labs, Dr Richard Sayre, who is one of the foremost plant mol biologists in the world. https://traitbio.com/about/.
Unfortunately, Trait seems to be still in private hands. It is a bit concerning that the CDN producers generally don't seem to have strong scientific staffs, so I wonder if the growers (all companies) are keeping up with the science.
Bullboard Posts